REFERENCES
1. Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, et al. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol 2011;122:155-70.
2. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-12.
3. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188-97.
4. Bevan RJ, Evans R, Griffiths L, Watkins LM, Rees MI, et al. Meningeal inflammation and cortical demyelination in acute multiple sclerosis. Ann Neurol 2018;84:829-42.
5. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 2007;17:38-44.
6. Calabrese M, Magliozzi R, Ciccarelli O, Geurts JJ, Reynolds R, et al. Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 2015;16:147-58.
7. Calabrese M, Romualdi C, Poretto V, Favaretto A, Morra A, et al. The changing clinical course of multiple sclerosis: a matter of gray matter. Ann Neurol 2013;74:76-83.
8. Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101-7.
9. Calabrese M, Rinaldi F, Mattisi I, Bernardi V, Favaretto A, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77:257-63.
10. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64:247-54.
11. Scalfari A, Romualdi C, Nicholas RS, Mattoscio M, Magliozzi R, et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology 2018;90:e2107-18.
12. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, et al. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005;64:1101-7.
13. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-104.
14. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 2014;14:447-62.
15. Bø L, Vedeler C, Nyland H, rapp BD, Mørk SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323-31.
16. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010;68:477-93.
17. Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 2019;10:1-14.
18. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011;134:2755-71.
19. Haider L, Zrzavy T, Hametner S, Höftberger R, Bagnato F, et al. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 2016;139:807-15.
20. Bø L, Vedeler C a, Nyland HI, Trapp BD, Mørk SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003;62:723-32.
21. Lassmann H, Raine CS, Antel J, Prineas JW. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 1998;86:213-7.
22. Mai JK, George Paxinos TV. Atlas of the Human Brain. 3rd edition. Academic Press; 2007.
23. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-74.
24. Motulsky HJ. ‘When to choose a nonparametric test’. GraphPad Stat. Guid. Available from: https://www.graphpad.com/guides/prism/8/statistics/index.htm [Last accessed on 2 Mar 2020].
25. Carassiti D, Altmann DR, Petrova N, Pakkenberg B, Scaravilli F, et al. Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex. Neuropathol Appl Neurobiol 2018;44:377-90.
26. Trapp BD, Vignos M, Dudman J, Chang A, Fisher E, et al. Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurol 2018;17:870-84.
27. Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, et al. Cortical demyelination in PML and MS: similarities and differences. Neurology 2008;70:336-43.
28. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650-3.
29. Fadda G, Brown RA, Magliozzi R, Aubert-Broche B, O’Mahony J, et al. A surface-in gradient of thalamic damage evolves in pediatric multiple sclerosis. Ann Neurol 2019;85:340-51.
30. Liu Z, Pardini M, Yaldizli O, Sethi V, Muhlert N, et al. Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis. Brain 2015;138:1239-46.
31. Kearney H, Yiannakas MC, Samson RS, Wheeler-Kingshott CA, Ciccarelli O, et al. Investigation of magnetization transfer ratio-derived pial and subpial abnormalities in the multiple sclerosis spinal cord. Brain 2014;137:2456-68.
32. Samson RS, Cardoso MJ, Muhlert N, Sethi V, Wheeler-Kingshott CA, et al. Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups. Mult Scler 2014;20:1322-30.
33. Mainero C, Louapre C, Govindarajan ST, Giannì C, Nielsen AS, et al. A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging. Brain 2015;138:932-45.
34. Absinta M, Vuolo L, Rao A, Nair G, Sati P, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 2015;85:18-28.
35. Zurawski J, Tauhid S, Chu R, Khalid F, Healy BC, et al. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult Scler 2020;26:177-87.
36. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology 2007;68:634-42.
37. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188-97.
38. Guseo A, Jellinger K. The significance of perivascular infiltrations in multiple sclerosis. J Neurol 1975;211:51-60.
39. Adams CW. Pathology of multiple sclerosis: progression of the lesion. Br Med Bull 1977;33:15-20.
40. Dawson JW. XVIII.-the histology of disseminated sclerosis. Trans R Soc Edinburgh 1916;50:517-740.
41. Howell OW, Schulz-Trieglaff EK, Carassiti D, Gentleman SM, Nicholas R, et al. Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space. Neuropathol Appl Neurobiol 2015;41:798-813.
42. DeLuca GC, Alterman R, Martin JL, Mittal A, Blundell S, et al. Casting light on multiple sclerosis heterogeneity: the role of HLA-DRB1 on spinal cord pathology. Brain 2013;136:1025-34.
43. Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, et al. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 2010;68:465-76.
44. Brown DA, Sawchenko PE. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J Comp Neurol 2007;502:236-60.
45. Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012;135:2925-37.
46. Gardner C, Magliozzi R, Durrenberger PF, Howell OW, Rundle J, et al. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain 2013;136:3596-608.
47. Magliozzi R, Howell OW, Nicholas R, Cruciani C, Castellaro M, et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol 2018;83:739-55.
48. Magliozzi R, Hametner S, Facchiano F, Marastoni D, Rossi S, et al. Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. Ann Clin Transl Neurol 2019;6:2150-63.
49. Schirmer L, Velmeshev D, Holmqvist S, Kaufmann M, Werneburg S, et al. Neuronal vulnerability and multilineage diversity in multiple sclerosis. Nature 2019;573:75-82.
50. Watkins LM, Neal JW, Loveless S, Michailidou I, Ramaglia V, et al. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. J Neuroinflammation 2016;13:161.
51. Klaver R, Popescu V, Voorn P, Galis-de Graaf Y, van der Valk P, et al. Neuronal and axonal loss in normal-appearing gray matter and subpial lesions in multiple sclerosis. J Neuropathol Exp Neurol 2015;74:453-8.
52. Jürgens T, Jafari M, Kreutzfeldt M, Bahn E, Brück W, et al. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. Brain 2016;139:39-46.
53. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
54. Fischer MT, Wimmer I, Höftberger R, Gerlach S, Haider L, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 2013;136:1799-815.
55. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011;134:1914-24.
56. Witte ME, Nijland PG, Drexhage JAR, Gerritsen W, Geerts D, et al. Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol 2013;125:231-43.
57. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012;8:647-56.
58. Campbell G., Ziabreva I, Reeve A, Krishnan KJ, Reynolds R, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 2011;69:481-92.
59. Ofengeim D, Ito Y, Trapp B, Zhang Y, Shan B, et al. Activation of necroptosis in multiple sclerosis. Cell Rep 2015;10:1836-49.
60. Magliozzi R, Howell OW, Durrenberger P, Aricò E, James R, et al. Meningeal inflammation changes the balance of TNF signalling in cortical grey matter in multiple sclerosis. J Neuroinflammation 2019;16:259.
61. Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, et al. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol 2012;246:85-95.
62. Lisak RP, Nedelkoska L, Benjamins JA, Schalk D, Bealmear B, et al. B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. J Neuroimmunol 2017;309:88-99.
63. Torkildsen Ø, Stansberg C, Angelskår SM, Kooi EJ, Geurts JJ, et al. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol 2010;20:720-9.
64. Crick PJ, Griffiths WJ, Zhang J, Beibel M, Abdel-Khalik J, et al. Reduced plasma levels of 25-hydroxycholesterol and increased cerebrospinal fluid levels of bile acid precursors in multiple sclerosis patients. Mol Neurobiol 2017;54:8009-20.
65. Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, et al. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain 2014;137:2271-86.
66. Castle D, Wynford-Thomas R, Loveless S, Bentley E, Howell OW, et al. Using biomarkers to predict clinical outcomes in multiple sclerosis. Pract Neurol 2019;19:342-9.
67. Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014;383:2213-21.
68. Kilsdonk ID, Jonkman LE, Klaver R, van Veluw SJ, Zwanenburg JJ, et al. Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. Brain 2016;139:1472-81.
69. Haider L, Simeonidou C, Steinberger G, Hametner S, Grigoriadis N, et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry 2014;85:1386-95.
